Polaryx Therapeutics reported cash from operations of -$1.33M and free cash flow of -$1.33M for the quarter ended Jun 2026, down 87.9% year over year. This cash flow statement covers 6 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2024 | Mar2025 | Jun2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | -5.05M | -0.88M | -1.96M | -1.38M | ||
| Share-based CompensationStock Comp. | 2.67M | 4.45M | 0.11M | 4.19M | 7.60M | 7.60M |
| Cash from OperationsCash from Ops. | -0.71M | -0.89M | -2.10M | -1.33M | ||
| Change in Working Capital | ||||||
| Change in Account PayablesChange Payables | -0.02M | 0.10M | 0.38M | -0.17M | ||
| Change in Accured ExpensesChange Accured Exp. | -0.09M | 0.01M | ||||
| Financing Activities | ||||||
| Cash from Financing ActivitiesCash from Financing | 0.25M | |||||
| Change in Capital Stock | ||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 0.11M | 0.58M | ||||
| Net Equity Issued and RepurchasedNet Equity Issued | 0.25M | |||||
| Additional items | ||||||
| Change in Cash | -0.46M | -0.86M | -2.06M | 8.46M | ||
| Free Cash FlowFCF | -0.71M | -0.89M | -2.10M | -1.33M | ||
| Net Cash FlowNCF | -0.46M | -0.89M | -2.10M | -1.33M |